Valuation: Veru Inc.

Market Cap 42.63M 37.25M 35.01M 31.95M 59.96M 4.07B 59.97M 420M 162M 2.08B 160M 157M 6.71B P/E 2026 *
-2.87x
P/E 2027 * -2.73x
Enterprise Value 42.63M 37.25M 35.01M 31.95M 59.96M 4.07B 59.97M 420M 162M 2.08B 160M 157M 6.71B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day+2.46%
1 week+6.84%
Current month-10.71%
1 month-5.30%
3 months-15.54%
6 months+10.13%
Current year+16.82%
1 week 2.35
Extreme 2.3489
2.52
1 month 2.29
Extreme 2.29
2.85
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
13/08/26 Buy

Chief Technology Officer

1,800 0.0112%
04/05/26 Free

Director

160,000 0.9969%
04/05/26 Free

Director

102,000 0.6355%
Change 5-day change 1-year change 3-year change Capi.($)
+2.46%+6.84%-29.97%-71.16% 42.63M
-0.07%+7.14%+53.95%+111.00% 74.27B
-0.16%+0.59%+36.14%+78.88% 61.21B
+0.28%+5.73%+33.67%+20.82% 27.55B
-0.15%+0.75%-16.69%+361.67% 26.38B
+2.93%+4.32%+2.18%-3.60% 25.34B
+0.97%+4.30%+26.36%-8.53% 20.84B
-1.47%+4.86%-5.94%+519.63% 14.94B
+0.87%-3.73%+159.95%+327.53% 15.17B
+1.63%+2.20%+46.92%+170.72% 14.41B
Average +0.73%+3.54%+30.66%+150.70% 28.02B
Weighted average by Cap. +0.34%+3.44%+36.85%+136.03%

Financials

2026 *2027 *
Net sales - -
Net income -23.3M -20.36M -19.14M -17.46M -32.78M -2.23B -32.78M -230M -88.63M -1.14B -87.5M -85.58M -3.67B -36.6M -31.98M -30.06M -27.43M -51.49M -3.5B -51.5M -361M -139M -1.79B -137M -134M -5.76B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
22/09/26 $2.500 +2.46% 121,369
21/09/26 $2.440 +1.24% 158,316
18/09/26 $2.410 +0.84% 103,031
17/09/26 $2.390 +3.02% 93,916
16/09/26 $2.320 -0.85% 130,344
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.500USD
Average target price
24.50USD
Spread / Average Target
+880.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!